ClinicalTrials.gg
Status unknownNCT05579418Updated Oct 13, 2022

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

A Phase 4 interventional study of Evolocumab in STEMI and Dyslipidemias, sponsored by Hamad Medical Corporation. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-13.

Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor compliance with medications. Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality in patients with atherosclerotic cardiovascular disease (ASCVD), with a magnitude of clinical benefit that is proportional to the reduction in LDL-C levels. Proprotein convertase subtilisin/ kexin type 9 (PCSK9) antibodies have emerged as a new class of drugs that rapidly and effectively lower LDL-C levels up to 77 % of the original value in combination with statins.

The primary objective of this study is to confirm the safety and the long-term clinical benefit associated with the use of PCSK9i when combined with statin in patients with ACS-STEMI.

The study is an investigator-initiated, prospective, randomized, open label study that will be the first study looking for the safety and the clinical benefit and outcome associated with the use of PCSK9i in ACS-STEMI patients specifically. Internationally, this will be the first trial studying the effect of PCSK9i on patients with acute myocardial infarction (STEMI) in terms of reduction in cholesterol level and reduction in cardiac events rate (re-infarction and cardiac death) after myocardial infarction. This trial will have a significant impact in the management of patients with STEMI, locally and internationally and it will be conducted purely in Qatar. This trial will help to improve the clinical outcome of patients in Qatar in terms of reduction of myocardial reinfarction rate and mortality.

Read the detailed description

The study is an investigator-initiated, prospective, randomized, open-label study. Patients will be eligible for participation in the trial if they are between 18-70 years of age. All patients presenting with STEMI will be screened for the trial, those patients with LDL-C levels higher than guideline-recommended targets despite prior high-intensity statin therapy (on statin therapy prior to hospital admission), or when the LDL-C not projected to decrease below the recommended targets if they are newly initiated on high intensity statin therapy, will be considered for the study.

Procedures and study interventions.

  1. Patients hospitalized for ST-segment elevation myocardial infarction [STEMI] with symptom onset \<12 h prior to hospitalization) will be potentially eligible.
  2. Patient will receive the standard care as per the HH guidelines in terms of coronary angiogram, standard therapy of statin, dual antiplatelet, B -Blockers and ACE.
  3. These patients will be screened for suitability to participate in the study
  4. The patients will be considered for enrolment if he/she is hemodynamically stable and had a successful PPCI to De-novo lesion in an infarct related artery (NOT stent thrombosis- those will be excluded from the study, also acute occlusion of cardiac grafts will be excluded from the study as well).
  5. LDL- C will be assessed immediately post angiography: The patient will be eligible for the trial if the LDL-C levels at the screening blood test is one of the following:

    >1.8 mmol/l if patients are on stable (unchanged for >4 weeks before screening) treatment with high-intensity statin.

    2.3 mmol/l in patients previously taking low- or moderate-intensity statin. 3.2 mmol/l in patients not on statin treatment.

  6. Eligible patients will be randomly assigned in a 1:1 ratio to one of the two groups: The control group or the intervention group.
  7. The control group will receive the standard, guidelines directed optimal medical therapy.
  8. The interventional group will receive Evolocumab 140 mg every 2 weeks in addition to the standard, guideline directed, optimal medical therapy.
  9. The optimal medical therapy will include high intensity statin (either atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg /day throughout the study) or maximal tolerated statin (in both groups the statin dose can be titrated up or down as per the standard clinical practice).
  10. The study drug will be administered at baseline as early as possible but within 24 hr following hospitalization. In our institute, patients admitted with STEMI will receive primary percutaneous intervention by default. The average time for door to balloon time is around 50 minutes (department data). Randomization and drug administration is not possible within such a short time, in addition consider randomization and drug administration before angiography may results in delay of delivering standard therapy which is of not in the best interest of the patient.
  11. The randomization will be done immediately after angiography and aim for drug administration within 24 hr of admission.
  12. Blood samples will be obtained at baseline for assessment of fasting lipids and inflammatory markers.
  13. All patients recruited for the trial, will receive medical treatment for ACS as per the Heart hospital and international guidelines. Patients that will be considered for the trial should have received coronary angiography and revascularization (percutaneous coronary intervention) as per the hospital guidelines.
  14. Patients not fit or rejected re-vascularization with PCI or patient that will need coronary artery bypass grafting [CABG] surgery) will be excluded from this study.
  15. Written informed consent will be obtained from all the patients.
  16. The research team may ask for supervised injection when suspect non-compliance.

Information and investigation that will be collected from patient:

  1. Patient will have blood test: Lipid panel, Liver function, and CRP will be done at 0,1, 2, 6 and 12, 18, and 24 months.
  2. Carotid intimal thickening measurement: at 0, 6, 12, 24 months
  3. Echocardiogram: 1,6,12,24 months
  4. OPD Review for clinical evaluation: medication side effect, Chest pain, hospitalization or unplanned PCI at 1,2,3,6,12,18,24 months.

Randomization:

Participants will be randomly assigned using permuted block design with a computer random number generator, the block size is fixed (8 per block) with random allocation within the block to either the control group or the interventional group. of the patients (4 for each group, patient allocation within the block is randomly assigned). Once the patient has given consent to be included in the trial, he/she is then irreversibly randomized by opening the next sealed envelope, within the current block, containing his/her assignment.

The production of computer-generated sets of random allocations will be done by a research support unit (who will not be performing data collection) in advance of the start of the study.

Sample size calculation:

Our study is designed as a superiority trial powered for the primary endpoint. The average LDL-D cholesterol of patients admitted with ACS-STEMI to the Heart Hospital was 3.4 mmol based on calculating the average LDL-C of 150 patients with ACS-STEMI in the past 6 months (department Data).

Bases on the EVOPACS study above, statin alone therapy will reduce the LDL-C by 35 % (1.19 mmol), while Evolocumab + statin combination therapy will reduce LDL-C by 77 % (2.61 mmol). Expectations for cholesterol-lowering trials were set by the Cholesterol Treatment Trialists' Collaborators, who reported in 2005 that for each 1 mmol/L (38.6 mg/dL) reduction in LDL-C, cardiovascular events were reduced by a mean of 22%. Based on this, the expected reduction in cardiovascular event is 26 % with statin therapy alone and 57 % with Evolocumab + statin. Assuming 1000 cases of ACS-STEMI present to our emergency department every year, and event rate of 17-33 % post STEMI patient for those on moderate to high intensity statins at one year, 90 % power and 5 % significance level, the sample size was 144 for each arm. Accounting for the nature of the country of high travel and dropout nature, 20 % drop rate was added to the sample size, the final sample size for this trial was up rounded to 350 patients (originally was 346).

02

Conditions studied

  • STEMI
  • Dyslipidemias

Keywords

  • STEMI
  • PCSK9i
  • Evolocumab
  • Statin
03

In context

ST Elevation Myocardial Infarction

851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 199 are open to participants now.

This study's planned enrollment of 350 is above the median of 194 across 529 interventional studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Inclusion and exclusion criteria:

Inclusion Criteria

  • Male or female ≥ 18 years of age and less than 80 years
  • Hospitalized for a recent ACS-STEMI within 12 hours of onset of symptoms.
  • Successful revascularization with PCI.
  • LDL-C levels defined as follows:

    • LDL-C ≥1.8 mmol/L in patients who have been receiving stable treatment with high-intensity statin within ≥ 4 weeks prior to enrollment (i.e., continuous treatment that has not changed with regard to statin intensity over the past 4 weeks)
    • LDL-C ≥2.3 mmol/L in patients who have been receiving stable treatment with low- or moderate-intensity statin within ≥ 4 weeks prior to enrollment (i.e., continuous treatment that has not changed with regard to statin intensity over the past 4 weeks)
    • LDL-C ≥3.2 mmol/L in patients who are statin-naïve or have not been on a stable (unchanged) statin regimen for at least 4 weeks prior to enrollment.
  • Ability to understand the requirements of the study and to provide

Exclusion criteria

  • Unstable clinical status (hemodynamic or electrical instability)
  • Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation or flutter with rapid ventricular response not controlled by medications in the past 3 months prior to screening
  • Severe renal dysfunction, defined by estimated \<30 ml/min/1.73m2
  • Active liver disease or hepatic dysfunction, either reported in patient medical record or defined by (AST) or alanine aminotransferase (ALT) levels > 3x the .
  • Patient need urgent CABG
  • patients symptoms onset is more than 12 hours.
  • Reported intolerance to atorvastatin (any dose) OR statin intolerance defined by the following criteria:

    • inability to tolerate at least 2 different statins (one statin at the lowest starting average daily dose and the other statin at any dose).
    • intolerance associated with confirmed, intolerable statin-related adverse effect(s) or significant biomarker abnormalities.
    • symptom or biomarker changes resolution or significant improvement upon dose decrease or discontinuation.
  • Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel
  • Known sensitivity to any substances or medication to be administered during the trial
  • Patients who previously received Evolocumab or other PCSK9 inhibitor
  • Treatment with systemic or systemic cyclosporine in the past 3 months.
  • Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator
  • Patients who will not be available for study-required procedures in the judgment of the Investigator
  • Current enrollment in another device or drug study
  • Active requiring treatment
  • Pregnant women. For female of (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy, pregnancy is excluded by a pregnancy test prior to inclusion in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Active comparator
    Interventional Arm

    Patient that qualify for the trial will be randomized for receiving the PCSK9i injection in addition to the standard medical therapy.

    Drug: Evolocumab

  • No intervention
    Control Arm

    Patient will only receive the standard medical therapy, No PCSK9i

Interventions

  • Evolocumab is an injection for management of dyslipidemia

    Also known as: Repatha

06

What researchers measure

Primary outcomes

  1. Major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

    The primary objective of this study is to confirm the safety and the long-term clinical benefit associated with the use of PCSK9i in combination with statin in patients with ACS-STEMI. The long terms clinical benefit is the reduction in major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

    Time frame: 12 months

  2. The safety of PCSK9i in patients with STEMI

    The safety of PCSK9i use in patients admitted with STEMI in terms of adverse events and complications related to the use of PCSK9i.

    Time frame: 12 months

Secondary outcomes

  1. Percentage change in calculated LDL-C from baseline to end of study period.

    The changes noted in the LDL-C levels from baseline ( time of recruitment) to end of study period.

    Time frame: 12 months

  2. Changes in carotid intimal thickening from baseline to the end of study period

    The intima-medial thickness of common carotid artery will evaluated by B-mode ultrasound imaging, the delta changes in the carotid intima-medial thickness will be calculated.

    Time frame: 12 months

  3. Adverse events and serious adverse events reported during study period.

    Any adverse events whether expected or not expected will be record and tabulated. These adverse events will be compared with the control group.

    Time frame: 12 months

  4. Changes in High-sensitivity C-reactive protein from baseline to the end of study period

    Changes in High-sensitivity C-reactive protein from baseline to the end of study period

    Time frame: 12 months

  5. Changes in left ventricular ejection fraction from baseline to the end of study period .

    Changes in left ventricular ejection fraction from baseline to the end of study period will be measured using echocardiogram.

    Time frame: 12 months

  6. Individual major cardiovascular events, defined as the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

    The effect of PCSK9i use in STEMI patients for each of the outcome individually including: cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All patients details will be stored in an electronic database and will be shared if a request submitted to institution research board and approved.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 10 years

Access criteria: Request has to be approved by PI and Heart Hospital Research Advisory Board.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2022; primary completion for Oct 2024, 23 months later.

Of 49 phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 13, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
Oct 30, 2024
CompletionEst.
Oct 30, 2024
Last update
Oct 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05579418
Responsible party
Dr. Mohammed Thamer Ali (Consultant Interventional Cardiologist, Hamad Medical Corporation) — Principal investigator
First posted
Oct 13, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Oct 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Oct 13, 2022

Study contacts

MOHAMMED ALI, MD
Contact
mali80@hamad.qa
0097433820545
Ahmed Rudwan, MD
Contact
arudwan@hamad.qa
0097455461103
Mohammed Ali, MD
principal investigator · Hamad Medical Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion